<?xml version='1.0' encoding='utf-8'?>
<document id="31649848"><sentence text="Cilastatin protects against imipenem-induced nephrotoxicity via inhibition of renal organic anion transporters (OATs)."><entity charOffset="0-10" id="DDI-PubMed.31649848.s1.e0" text="Cilastatin" /><entity charOffset="28-36" id="DDI-PubMed.31649848.s1.e1" text="imipenem" /><pair ddi="false" e1="DDI-PubMed.31649848.s1.e0" e2="DDI-PubMed.31649848.s1.e0" /><pair ddi="false" e1="DDI-PubMed.31649848.s1.e0" e2="DDI-PubMed.31649848.s1.e1" /></sentence><sentence text="Imipenem is a carbapenem antibiotic"><entity charOffset="0-8" id="DDI-PubMed.31649848.s2.e0" text="Imipenem" /><entity charOffset="14-24" id="DDI-PubMed.31649848.s2.e1" text="carbapenem" /><pair ddi="false" e1="DDI-PubMed.31649848.s2.e0" e2="DDI-PubMed.31649848.s2.e0" /><pair ddi="false" e1="DDI-PubMed.31649848.s2.e0" e2="DDI-PubMed.31649848.s2.e1" /></sentence><sentence text=" However, Imipenem could not be marketed owing to its instability and nephrotoxicity until cilastatin, an inhibitor of renal dehydropeptidase-I (DHP-I), was developed"><entity charOffset="10-18" id="DDI-PubMed.31649848.s3.e0" text="Imipenem" /><entity charOffset="91-101" id="DDI-PubMed.31649848.s3.e1" text="cilastatin" /><pair ddi="false" e1="DDI-PubMed.31649848.s3.e0" e2="DDI-PubMed.31649848.s3.e0" /><pair ddi="false" e1="DDI-PubMed.31649848.s3.e0" e2="DDI-PubMed.31649848.s3.e1" /></sentence><sentence text=" In present study, the potential roles of renal organic anion transporters (OATs) in alleviating the nephrotoxicity of imipenem by cilastatin were investigated in vitro and in rabbits"><entity charOffset="119-127" id="DDI-PubMed.31649848.s4.e0" text="imipenem" /><entity charOffset="131-141" id="DDI-PubMed.31649848.s4.e1" text="cilastatin" /><pair ddi="false" e1="DDI-PubMed.31649848.s4.e0" e2="DDI-PubMed.31649848.s4.e0" /><pair ddi="false" e1="DDI-PubMed.31649848.s4.e0" e2="DDI-PubMed.31649848.s4.e1" /></sentence><sentence text=" Our results indicated that imipenem and cilastatin were substrates of hOAT1 and hOAT3"><entity charOffset="28-36" id="DDI-PubMed.31649848.s5.e0" text="imipenem" /><entity charOffset="41-51" id="DDI-PubMed.31649848.s5.e1" text="cilastatin" /><pair ddi="false" e1="DDI-PubMed.31649848.s5.e0" e2="DDI-PubMed.31649848.s5.e0" /><pair ddi="false" e1="DDI-PubMed.31649848.s5.e0" e2="DDI-PubMed.31649848.s5.e1" /></sentence><sentence text=" Cilastatin inhibited hOAT1/3-mediated transport of imipenem with IC50 values comparable to the clinical concentration, suggesting the potential to cause a clinical drug-drug interaction (DDI)"><entity charOffset="1-11" id="DDI-PubMed.31649848.s6.e0" text="Cilastatin" /><entity charOffset="52-60" id="DDI-PubMed.31649848.s6.e1" text="imipenem" /><pair ddi="false" e1="DDI-PubMed.31649848.s6.e0" e2="DDI-PubMed.31649848.s6.e0" /><pair ddi="false" e1="DDI-PubMed.31649848.s6.e0" e2="DDI-PubMed.31649848.s6.e1" /></sentence><sentence text=" Moreover, imipenem exhibited hOAT1/3-dependent cytotoxicity, which was alleviated by cilastatin and probenecid"><entity charOffset="11-19" id="DDI-PubMed.31649848.s7.e0" text="imipenem" /><entity charOffset="86-96" id="DDI-PubMed.31649848.s7.e1" text="cilastatin" /><entity charOffset="101-111" id="DDI-PubMed.31649848.s7.e2" text="probenecid" /><pair ddi="false" e1="DDI-PubMed.31649848.s7.e0" e2="DDI-PubMed.31649848.s7.e0" /><pair ddi="false" e1="DDI-PubMed.31649848.s7.e0" e2="DDI-PubMed.31649848.s7.e1" /><pair ddi="false" e1="DDI-PubMed.31649848.s7.e0" e2="DDI-PubMed.31649848.s7.e2" /><pair ddi="false" e1="DDI-PubMed.31649848.s7.e1" e2="DDI-PubMed.31649848.s7.e1" /><pair ddi="false" e1="DDI-PubMed.31649848.s7.e1" e2="DDI-PubMed.31649848.s7.e2" /></sentence><sentence text=" Furthermore, cilastatin and probenecid ameliorated imipenem-induced rabbit acute kidney injury, and reduced the renal secretion of imipenem"><entity charOffset="14-24" id="DDI-PubMed.31649848.s8.e0" text="cilastatin" /><entity charOffset="29-39" id="DDI-PubMed.31649848.s8.e1" text="probenecid" /><entity charOffset="52-60" id="DDI-PubMed.31649848.s8.e2" text="imipenem" /><entity charOffset="132-140" id="DDI-PubMed.31649848.s8.e3" text="imipenem" /><pair ddi="false" e1="DDI-PubMed.31649848.s8.e0" e2="DDI-PubMed.31649848.s8.e0" /><pair ddi="false" e1="DDI-PubMed.31649848.s8.e0" e2="DDI-PubMed.31649848.s8.e1" /><pair ddi="false" e1="DDI-PubMed.31649848.s8.e0" e2="DDI-PubMed.31649848.s8.e2" /><pair ddi="false" e1="DDI-PubMed.31649848.s8.e0" e2="DDI-PubMed.31649848.s8.e3" /><pair ddi="false" e1="DDI-PubMed.31649848.s8.e1" e2="DDI-PubMed.31649848.s8.e1" /><pair ddi="false" e1="DDI-PubMed.31649848.s8.e1" e2="DDI-PubMed.31649848.s8.e2" /><pair ddi="false" e1="DDI-PubMed.31649848.s8.e1" e2="DDI-PubMed.31649848.s8.e3" /><pair ddi="false" e1="DDI-PubMed.31649848.s8.e2" e2="DDI-PubMed.31649848.s8.e2" /><pair ddi="false" e1="DDI-PubMed.31649848.s8.e2" e2="DDI-PubMed.31649848.s8.e3" /></sentence><sentence text=" Cilastatin and probenecid inhibited intracellular accumulation of imipenem and sequentially decreased the nephrocyte toxicity in rabbit primary proximal tubule cells"><entity charOffset="1-11" id="DDI-PubMed.31649848.s9.e0" text="Cilastatin" /><entity charOffset="67-75" id="DDI-PubMed.31649848.s9.e1" text="imipenem" /><pair ddi="false" e1="DDI-PubMed.31649848.s9.e0" e2="DDI-PubMed.31649848.s9.e0" /><pair ddi="false" e1="DDI-PubMed.31649848.s9.e0" e2="DDI-PubMed.31649848.s9.e1" /></sentence><sentence text=" Renal OATs, besides DHP-I, was also the target of interaction between imipenem and cilastatin, and contributed to the nephrotoxicity of imipenem"><entity charOffset="71-79" id="DDI-PubMed.31649848.s10.e0" text="imipenem" /><entity charOffset="84-94" id="DDI-PubMed.31649848.s10.e1" text="cilastatin" /><entity charOffset="137-145" id="DDI-PubMed.31649848.s10.e2" text="imipenem" /><pair ddi="false" e1="DDI-PubMed.31649848.s10.e0" e2="DDI-PubMed.31649848.s10.e0" /><pair ddi="false" e1="DDI-PubMed.31649848.s10.e0" e2="DDI-PubMed.31649848.s10.e1" /><pair ddi="false" e1="DDI-PubMed.31649848.s10.e0" e2="DDI-PubMed.31649848.s10.e2" /><pair ddi="false" e1="DDI-PubMed.31649848.s10.e1" e2="DDI-PubMed.31649848.s10.e1" /><pair ddi="false" e1="DDI-PubMed.31649848.s10.e1" e2="DDI-PubMed.31649848.s10.e2" /></sentence><sentence text=" This therefore gives in part the explanation about the mechanism by which cilastatin protected against imipenem-induced nephrotoxicity"><entity charOffset="75-85" id="DDI-PubMed.31649848.s11.e0" text="cilastatin" /><entity charOffset="104-112" id="DDI-PubMed.31649848.s11.e1" text="imipenem" /><pair ddi="false" e1="DDI-PubMed.31649848.s11.e0" e2="DDI-PubMed.31649848.s11.e0" /><pair ddi="false" e1="DDI-PubMed.31649848.s11.e0" e2="DDI-PubMed.31649848.s11.e1" /></sentence><sentence text=" Thus, OATs can potentially be used as a therapeutic target to avoid the renal adverse reaction of imipenem in clinic"><entity charOffset="99-107" id="DDI-PubMed.31649848.s12.e0" text="imipenem" /></sentence><sentence text="" /></document>